Aytu BioPharma, Inc.
AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 yeaā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.37
Price+3.95%
$0.09
1Y
Price
Market Cap
$25.438m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-32.6%
EBITDA Margin-45.3%
Net Profit Margin-33.7%
Free Cash Flow Margin-32.6%
EBITDA Margin-45.3%
Net Profit Margin-33.7%
Free Cash Flow MarginRevenue
$56.599m
-14.7%
1y CAGR-17.4%
3y CAGR-10.3%
5y CAGREarnings
-$34.055m
-151.1%
1y CAGR-43.2%
3y CAGR-11.3%
5y CAGREPS
-$4.58
-112.0%
1y CAGR-14.5%
3y CAGR+12.4%
5y CAGRBook Value
$35.143m
$111.689m
Assets$76.546m
Liabilities$22.938m
DebtDebt to Assets
20.5%
-0.8x
Debt to EBITDAFree Cash Flow
$1.644m
+131.8%
1y CAGR-0.8%
3y CAGR+19.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company